Biogen
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1978-01-01
- Employees
- 7.5K
- Market Cap
- $29.6B
- Website
- https://www.biogen.com
- Introduction
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMAD...
A Study to Determine the Absolute Bioavailability of BIIB122/DNL151 in Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2021-08-13
- Last Posted Date
- 2021-11-17
- Lead Sponsor
- Biogen
- Target Recruit Count
- 8
- Registration Number
- NCT05005338
- Locations
- 🇺🇸
Pharmaron CPC, Baltimore, Maryland, United States
Expanded Access Program for Tofersen in Participants With Superoxide Dismutase 1-Amyotropic Lateral Sclerosis
- First Posted Date
- 2021-07-22
- Last Posted Date
- 2024-06-10
- Lead Sponsor
- Biogen
- Registration Number
- NCT04972487
- Locations
- 🇺🇸
Research Site, Austin, Texas, United States
A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus
- First Posted Date
- 2021-07-14
- Last Posted Date
- 2024-08-06
- Lead Sponsor
- Biogen
- Target Recruit Count
- 540
- Registration Number
- NCT04961567
- Locations
- 🇺🇸
Swedish Medical Center, Seattle, Washington, United States
🇺🇸University of Cincinnati, Cincinnati, Ohio, United States
🇨🇳Nanfang Hospital of Southern Medical University, Guangzhou, Guangdong, China
Exploring Diroximel Fumarate Real-world Experience in Canada and Israel
- First Posted Date
- 2021-07-02
- Last Posted Date
- 2023-05-10
- Lead Sponsor
- Biogen
- Target Recruit Count
- 64
- Registration Number
- NCT04948606
- Locations
- 🇮🇱
Lady Davis Carmel Medical Center, Haifa, Israel
🇮🇱Meir Medical Center, Kfar Saba, Israel
🇮🇱Rabin Medical Center, Petah Tikva, Israel
A Study to Assess Absolute Bioavailability of Aducanumab in Healthy Volunteers
- First Posted Date
- 2021-06-11
- Last Posted Date
- 2023-04-13
- Lead Sponsor
- Biogen
- Target Recruit Count
- 30
- Registration Number
- NCT04924140
- Locations
- 🇺🇸
Anaheim Clinical Trials, LLC, Anaheim, California, United States
🇺🇸Qps-Mra, Llc, South Miami, Florida, United States
A Natural History Study of Participants With Potassium Sodium-Activated Channel Subfamily T Member 1 (KCNT1)-Related Epilepsy
- First Posted Date
- 2021-06-11
- Last Posted Date
- 2024-02-28
- Lead Sponsor
- Biogen
- Target Recruit Count
- 35
- Registration Number
- NCT04924153
- Locations
- 🇺🇸
University of Rochester, Rochester, New York, United States
A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus
- First Posted Date
- 2021-05-20
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Biogen
- Target Recruit Count
- 540
- Registration Number
- NCT04895241
- Locations
- 🇫🇷
Hopital Lapeyronie, Montpellier Cedex 5, Herault, France
🇵🇱Centrum Badawcze Panaceum Agnieszka Brzezicka, Magdalena Lenkiewicz Sp. z o.o., Malbork, Poland
🇵🇱MICS Centrum Medyczne Warszawa, Warszawa, Poland
A Study of BIIB067 (Tofersen) Initiated in Clinically Presymptomatic Adults With a Confirmed Superoxide Dismutase 1 Mutation
- Conditions
- Interventions
- First Posted Date
- 2021-04-23
- Last Posted Date
- 2024-06-11
- Lead Sponsor
- Biogen
- Target Recruit Count
- 150
- Registration Number
- NCT04856982
- Locations
- 🇺🇸
Emory University, Atlanta, Georgia, United States
🇺🇸Northwestern University, Chicago, Illinois, United States
🇺🇸Johns Hopkins Hospital, Baltimore, Maryland, United States
Study of Tysabri in Early Relapsing Remitting Multiple Sclerosis Participants
- First Posted Date
- 2021-04-05
- Last Posted Date
- 2024-02-05
- Lead Sponsor
- Biogen
- Target Recruit Count
- 60
- Registration Number
- NCT04832399
- Locations
- 🇵🇹
Research Site, Vila Nova de Gaia, Portugal
Natural Disease Progression in Participants With Choroideremia
- First Posted Date
- 2021-03-12
- Last Posted Date
- 2021-09-08
- Lead Sponsor
- Biogen
- Target Recruit Count
- 1178
- Registration Number
- NCT04795206
- Locations
- 🇺🇸
Research Site, San Francisco, California, United States